ALX Oncology Holdings Inc. reported financial results for the second quarter ended June 30, 2026, on August 6, 2026. The company posted a GAAP net loss of $18.0 million, or $0.13 per share, compared to a $25.9 million loss in the prior year period. Cash, cash equivalents, and investments totaled $153.4 million as of June 30, 2026. The company strengthened its balance sheet by refinancing existing debt with HSBC Ventures USA Inc., securing up to an additional $20 million draw through June 2028 under a new facility totaling up to $50 million. Leadership appointments included Scott Garland as Chairman of the Board and Michael Listgarten as General Counsel. Clinical updates indicated enrollment remains on track for the Phase 2 ASPEN-09-Breast trial evaluating evorpacept, with topline data expected in mid-2027, while initial safety data for ALX2004 is anticipated in the second half of 2026. ALX Oncology Holdings Inc. operates as a clinical-stage biotechnology company advancing novel cancer therapies.

Corey Goodman, Ph.D., resigned as Chairman of the Board and as a director for personal reasons, effective June 29, 2026. The Board appointed Scott Garland to serve as Chairman of the Board, effective the same day. The Board also reorganized its Audit, Compensation, and Corporate Governance and Nominating committees. ALX Oncology Holdings Inc. is a biotechnology company focused on developing oncology treatments.

ALX Oncology Holdings Inc. entered into a secured multi-tranche term loan agreement with HSBC Ventures USA Inc. on June 25, 2026. The facility provides up to $50,000,000 in aggregate principal, including $10,000,000 that is uncommitted. The company immediately borrowed $10,000,000 to refinance existing debt with Oxford Finance and Silicon Valley Bank. An additional $20,000,000 is available through June 30, 2028, with another $10,000,000 contingent upon positive clinical data from the Phase 2 ASPEN-09 study of Evorpacept and Phase 1 study of ALX2004. The loans mature on June 1, 2030, and carry a floating interest rate equal to the greater of the Prime Rate or 6.0%. ALX Oncology is a biotechnology company focused on developing cancer therapies.